The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) elected a new chair. Tim Leest starts his three─year mandate...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - STOCKHEAD.COM.AU - A La Une - 17/Sep 23:37
PharmAust seeks orphan drug designation in Europe for monepantel to treat ALS
Clinical-stage biotech PharmAust has submitted a request for orphan medicinal product designation (OMPD) to the European Medicines Agency (EMA) for ...
Articles similaires
Nolotil latest: ‘Benefits’ of painkiller ‘outweigh the risks’, say European health chiefs – despite scores of British deaths linked to the drug
theolivepress.es - 07/Sep 11:37
THE European Medicines Agency (EMA) has ruled out banning or bringing in tougher restrictions on controversial painkiller Nolotil – for now. The...
Nolotil latest: ‘Benefits’ of painkiller ‘outweigh the risks’, say European health chiefs – despite scores of British deaths linked to the drug
theolivepress.es - 07/Sep 11:37
THE European Medicines Agency (EMA) has ruled out banning or bringing in tougher restrictions on controversial painkiller Nolotil – for now. The...
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
zacks.com - 12/Sep 15:33
The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
zacks.com - 12/Sep 15:33
The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.
Key paediatric milestone reached in Dimerix’s kidney-disease drug trial
stockhead.com.au - 12/Sep 03:41
Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...
Key paediatric milestone reached in Dimerix’s kidney-disease drug trial
stockhead.com.au - 12/Sep 03:41
Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...
First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
drugs.com - 09/Sep 20:09
HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...
Imugene gets crucial FDA nod for bile tract cancer drug
thewest.com.au - 06:47
Imugene has landed a prized FDA orphan drug approval for its bile tract cancer therapy following positive results from its recent metastatic advanced...
Imugene gets crucial FDA nod for bile tract cancer drug
thewest.com.au - 06:47
Imugene has landed a prized FDA orphan drug approval for its bile tract cancer therapy following positive results from its recent metastatic advanced...
Les derniers communiqués
-
Aucun élément